In recent reports, the spectrum of mutations identified in the RET proto-oncogene in patients with MTC has shifted from the ‘classical’ and most prevalent worldwide mutation at codon 634 in exon 11 to clinically less aggressive forms with mutations in exons 13–15 [18–20]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.